It has been experimentally demonstrated that Zaragozionic acid, a pharmacological inhibitor of Squalene synthase (SQS), can lead to growth arrest and induction of cytotoxicity in prostate cancer cells (Brusselmans et al., 2007). The gene discussed is FDFT1; the disease is prostate carcinoma.